Suppression of angiogenesis and tumor growth by selective inhibition of angiopoietin-2 - PubMed (original) (raw)
doi: 10.1016/j.ccr.2004.09.030.
Hosung Min, Juan Leal, Dongyin Yu, Shashirekha Rao, Edward You, Xiu Tang, Haejin Kim, Susanne Meyer, Seog Joon Han, Nessa Hawkins, Robert Rosenfeld, Elyse Davy, Kevin Graham, Frederick Jacobsen, Shirley Stevenson, Joanne Ho, Qing Chen, Thomas Hartmann, Mark Michaels, Michael Kelley, Luke Li, Karen Sitney, Frank Martin, Ji-Rong Sun, Nancy Zhang, John Lu, Juan Estrada, Rakesh Kumar, Angela Coxon, Stephen Kaufman, James Pretorius, Sheila Scully, Russ Cattley, Marc Payton, Steve Coats, Linh Nguyen, Binodh Desilva, Anthony Ndifor, Isaac Hayward, Robert Radinsky, Tom Boone, Richard Kendall
Affiliations
- PMID: 15542434
- DOI: 10.1016/j.ccr.2004.09.030
Free article
Suppression of angiogenesis and tumor growth by selective inhibition of angiopoietin-2
Jonathan Oliner et al. Cancer Cell. 2004 Nov.
Free article
Abstract
Angiopoietin-2 (Ang2) exhibits broad expression in the remodeling vasculature of human tumors but very limited expression in normal tissues, making it an attractive candidate target for antiangiogenic cancer therapy. To investigate the functional consequences of blocking Ang2 activity, we generated antibodies and peptide-Fc fusion proteins that potently and selectively neutralize the interaction between Ang2 and its receptor, Tie2. Systemic treatment of tumor-bearing mice with these Ang2-blocking agents resulted in tumor stasis, followed by elimination of all measurable tumor in a subset of animals. These effects were accompanied by reduced endothelial cell proliferation, consistent with an antiangiogenic therapeutic mechanism. Anti-Ang2 therapy also prevented VEGF-stimulated neovascularization in a rat corneal model of angiogenesis. These results imply that specific Ang2 inhibition may represent an effective antiangiogenic strategy for treating patients with solid tumors.
Similar articles
- MEDI3617, a human anti-angiopoietin 2 monoclonal antibody, inhibits angiogenesis and tumor growth in human tumor xenograft models.
Leow CC, Coffman K, Inigo I, Breen S, Czapiga M, Soukharev S, Gingles N, Peterson N, Fazenbaker C, Woods R, Jallal B, Ricketts SA, Lavallee T, Coats S, Chang Y. Leow CC, et al. Int J Oncol. 2012 May;40(5):1321-30. doi: 10.3892/ijo.2012.1366. Epub 2012 Feb 10. Int J Oncol. 2012. PMID: 22327175 - Inhibition of in vivo tumor angiogenesis and growth via systemic delivery of an angiopoietin 2-specific RNA aptamer.
Sarraf-Yazdi S, Mi J, Moeller BJ, Niu X, White RR, Kontos CD, Sullenger BA, Dewhirst MW, Clary BM. Sarraf-Yazdi S, et al. J Surg Res. 2008 May 1;146(1):16-23. doi: 10.1016/j.jss.2007.04.028. Epub 2007 Oct 22. J Surg Res. 2008. PMID: 17950331 - Combination of vascular endothelial growth factor receptor/platelet-derived growth factor receptor inhibition markedly improves radiation tumor therapy.
Timke C, Zieher H, Roth A, Hauser K, Lipson KE, Weber KJ, Debus J, Abdollahi A, Huber PE. Timke C, et al. Clin Cancer Res. 2008 Apr 1;14(7):2210-9. doi: 10.1158/1078-0432.CCR-07-1893. Clin Cancer Res. 2008. PMID: 18381963 - Angiopoietin-2: an attractive target for improved antiangiogenic tumor therapy.
Gerald D, Chintharlapalli S, Augustin HG, Benjamin LE. Gerald D, et al. Cancer Res. 2013 Mar 15;73(6):1649-57. doi: 10.1158/0008-5472.CAN-12-4697. Epub 2013 Mar 6. Cancer Res. 2013. PMID: 23467610 Review. - Expression of vascular endothelial growth factor (VEGF) and VEGF receptors in tumor angiogenesis and malignancies.
Pradeep CR, Sunila ES, Kuttan G. Pradeep CR, et al. Integr Cancer Ther. 2005 Dec;4(4):315-21. doi: 10.1177/1534735405282557. Integr Cancer Ther. 2005. PMID: 16282508 Review.
Cited by
- Posterior eye delivery of angiogenesis-inhibiting RNA nanoparticles via subconjunctival injection.
Zhong C, Shi Z, Binzel DW, Jin K, Li X, Guo P, Li SK. Zhong C, et al. Int J Pharm. 2024 May 25;657:124151. doi: 10.1016/j.ijpharm.2024.124151. Epub 2024 Apr 23. Int J Pharm. 2024. PMID: 38657717 - Short Term Effect of Pre-Operative Anti-VEGF on Angiogenic and Fibrotic Profile of Fibrovascular Membranes of Proliferative Diabetic Retinopathy.
Fadakar K, Rahmani S, Tedeschi T, Lavine JA, Fawzi AA. Fadakar K, et al. Invest Ophthalmol Vis Sci. 2024 Apr 1;65(4):37. doi: 10.1167/iovs.65.4.37. Invest Ophthalmol Vis Sci. 2024. PMID: 38652648 Free PMC article. - Role of Angiogenesis and Its Biomarkers in Development of Targeted Tumor Therapies.
Pathak A, Pal AK, Roy S, Nandave M, Jain K. Pathak A, et al. Stem Cells Int. 2024 Jan 4;2024:9077926. doi: 10.1155/2024/9077926. eCollection 2024. Stem Cells Int. 2024. PMID: 38213742 Free PMC article. Review. - Phytochemicals Showing Antiangiogenic Effect in Pre-clinical Models and their Potential as an Alternative to Existing Therapeutics.
Senrung A, Tripathi T, Aggarwal N, Janjua D, Yadav J, Chaudhary A, Chhokar A, Joshi U, Bharti AC. Senrung A, et al. Curr Top Med Chem. 2024;24(4):259-300. doi: 10.2174/0115680266264349231016094456. Curr Top Med Chem. 2024. PMID: 37867279 Review. - Angiopoietin-2 blockade suppresses growth of liver metastases from pancreatic neuroendocrine tumors by promoting T cell recruitment.
Lee E, O'Keefe S, Leong A, Park HR, Varadarajan J, Chowdhury S, Hiner S, Kim S, Shiva A, Friedman RA, Remotti H, Fojo T, Yang HW, Thurston G, Kim M. Lee E, et al. J Clin Invest. 2023 Oct 16;133(20):e167994. doi: 10.1172/JCI167994. J Clin Invest. 2023. PMID: 37843277 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Molecular Biology Databases
Miscellaneous